This week, the European Commission proposed a “recalibration” of Supplementary Protection Certificates (SPCs) to boost investment in the development and manufacture of biosimilars and generics.
This week, the European Commission (EC) proposed a “recalibration” of Supplementary Protection Certificates (SPCs) to boost investment in the development and manufacture of biosimilars and generics.
An SPC is an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar. When it was first implemented, the SPC system sought to provide the pharmaceutical industry with sufficient incentives to develop innovative products within the European Union, and to prevent companies from relocating to other countries.
The new proposal seeks to amend the European Union’s legislation on SPCs to introduce a manufacturing exemption for export purposes during the term of an SPC. The exemption would restrict the protection conferred by the SPC in order to remove competitive disadvantages to EU-based generics and biosimilars manufacturers, namely by allowing a drug maker to manufacture a product in an EU member state for the sole purpose of exporting the product to a non-EU market (ie, a market that is not subject to an SPC).
According to the proposal, when in 2017, the EC launched a public consultation on SPCs, comments demonstrated broad support for the proposed waiver; while the SPC initially sought to spur innovation, the EC’s proposal notes that biosimilar and generic products will represent 80% of all medicines worldwide by volume in the year 2020, and SPCs keep EU-based manufacturers from producing any generics or biosimilars for a covered drug—even if the manufacture is exclusively for export to another market—during the protection period. “This problem puts EU-based industry at a disadvantage,” says the proposal, because manufacturers in non-EU countries do not fact the same restrictions.
Under the proposal, once an SPC has expired, biosimilar and generics companies who have established manufacturing lines for their export products will be able to use the same lines to manufacture products to supply the EU marketplace, an approach that the EC says will strengthen the EU supply chain.
The proposal notes that SPC protections will be left intact in the European Union, and that the EC will undertake a series of safeguards to ensure that products intended for export are not diverted to the EU market.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.